Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ulixertinib - BioMed Valley Discoveries

Drug Profile

Ulixertinib - BioMed Valley Discoveries

Alternative Names: BVD-523; BVD-523FB; BVD-ERK; BVD-ERK/HM; BVD-ERK/ST; VRT-0752271; VRT-752271; VX-271

Latest Information Update: 28 Apr 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer BioMed Valley Discoveries; Dana-Farber Cancer Institute; National Cancer Institute (USA)
  • Class Aminopyridines; Antineoplastics; Pyrroles; Small molecules
  • Mechanism of Action Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma; Solid tumours; Uveal melanoma
  • Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase I Pancreatic cancer

Most Recent Events

  • 28 Apr 2019 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, First-line therapy, Metastatic disease) in USA (PO)
  • 01 Oct 2018 Phase-II clinical trials in Non-Hodgkin's lymphoma (Recurrent, Second-line therapy or greater,In infants, In Children, Adolescents, In Adults) in USA (PO) (NCT03698994)
  • 01 Oct 2018 Phase-II clinical trials in Solid tumours (In infants, In Children, Adolescents, In Adults, Late-stage disease, Monotherapy) in USA (PO) (NCT03698994)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top